Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Volatile Valeant Substitutes Schiller For Ailing CEO

This article was originally published in Scrip

Executive Summary

With investors growing increasingly edgy over the lingering absence of Valeant Pharmaceuticals International Inc.'s ailing chairman and CEO Michael Pearson – whose hospitalization late last month due to severe pneumonia came in the midst of the company's struggle to rebuild its image after being mired in a scandal over its business practices – the firm's board on Jan. 6 appointed former chief financial officer Howard Schiller to take the helm in the interim.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC064140

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel